The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT)
survivors continues to increase. Among patients whose disease remains in remission for the …

Hematopoietic cell transplantation is a curative treatment for a variety of hematologic
diseases. Advances in transplantation technology have reduced early transplant-related …

Abstract The 2006 National Institutes of Health (NIH) Consensus paper presented
recommendations by the Ancillary Therapy and Supportive Care Working Group to support …

The number of patients surviving≥ 5 years after initial cancer diagnosis has significantly
increased during the last decades due to considerable improvements in the treatment of …

As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described
and the potential for extending their therapeutic benefit grows, optimizing the …

Total body irradiation (TBI), used as part of the conditioning regimen prior to allogeneic and
autologous hematopoietic cell transplantation, is the delivery of a relatively homogeneous …

Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free
survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant …

Chimeric antigen receptor T cell (CAR T) therapy has changed the treatment landscape of
relapsed/refractory lymphoid malignancies. With an expanding pool of post–CAR T cell …

COI notes: DWL has consulted for Harpoon Therapeutics, has advised for Amgen and BMS,
and has research funding from Kite Pharma and Gilead. SAG has research funding from …

Endocrine complications are frequently observed in childhood cancer survivors (CCS). One
of two CCS will experience at least one endocrine complication during the course of his/her …